文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于肺形态的个体化机械通气与低呼气末正压治疗急性呼吸窘迫综合征的比较(LIVE研究):一项多中心、单盲、随机对照试验

Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2019-08-06
一句话结论基于肺形态的个体化机械通气未降低中重度ARDS患者90天死亡率,但21%患者肺形态误分类,策略与肺形态不匹配者死亡率显著升高。

LIVE研究为法国20个ICU开展的多中心、单盲、随机对照试验,纳入420例中重度ARDS患者,比较基于肺形态的个体化通气策略(局灶型:潮气量8 mL/kg、低PEEP、俯卧位;非局灶型:潮气量6 mL/kg、肺复张手法、高PEEP)与标准治疗(潮气量6 mL/kg、低PEEP表、鼓励早期俯卧位)。意向性分析显示两组90天死亡率无差异(HR 1.01;95%CI 0.61-1.66;p=0.98)。但85例(21%)患者肺形态被研究者误分类,误分类与随机分组对主要终点存在显著交互作用(p<0.001);误分类亚组中个体化组90天死亡率高于对照组(26/40例[65%] vs 18/57例[32%];HR 2.8;95%CI 1.5-5.1;p=0.012)。作者认为个体化通气未降低死亡率,可能与21%患者误分类有关,与肺形态不匹配的通气策略大幅增加死亡率。

要点

  • 中重度ARDS患者中,基于肺形态的个体化机械通气与标准低PEEP策略相比,90天死亡率无差异(HR 1.01;95%CI 0.61-1.66;p=0.98)。
  • 400例可评估患者中85例(21%)肺形态被研究者误分类为局灶型或非局灶型。
  • 误分类与随机分组对主要终点存在显著交互作用(p<0.001)。
  • 误分类亚组中,个体化组90天死亡率65%(26/40)高于对照组32%(18/57),HR 2.8(95%CI 1.5-5.1;p=0.012)。
  • 作者认为与肺形态不匹配的通气策略大幅增加死亡率,改善ARDS表型分型能否降低死亡率需未来临床试验评估。

适用人群与场景

  • 法国20个大学或非大学ICU中年龄>18岁、早期ARDS持续<12小时的中重度ARDS患者。
  • 随机分组按研究中心、肺形态和机械通气持续时间分层。

诊断标准与关键阈值

  • 中重度ARDS且早期病程<12小时。
  • 肺形态分为局灶型与非局灶型,由研究者判定,误分类率21%(85/400)。

处置流程与药物剂量

  • 对照组:潮气量6 mL/kg(按预测体重),PEEP按低PEEP与吸入氧浓度表选择,鼓励早期俯卧位。
  • 个体化组局灶型ARDS:潮气量8 mL/kg,低PEEP,俯卧位。
  • 个体化组非局灶型ARDS:潮气量6 mL/kg,联合肺复张手法和高PEEP。

研究设计与关键结果

  • 多中心、单盲、分层、平行组随机对照试验,2014年6月12日至2017年2月2日随机分配420例患者;个体化组排除11例、对照组排除9例,最终分析个体化组196例、对照组204例。
  • 意向性分析中,个体化通气组与对照组90天死亡率无差异(HR 1.01;95%CI 0.61-1.66;p=0.98)。
  • 400例患者中85例(21%)被研究者误分类为局灶型或非局灶型ARDS。
  • 误分类与随机分组对主要终点存在显著交互作用(p<0.001)。
  • 误分类亚组中,个体化组90天死亡率65%(26/40)高于对照组32%(18/57),HR 2.8(95%CI 1.5-5.1;p=0.012)。

证据类型、等级与局限

  • 证据类型:多中心、单盲、随机对照试验。
  • 作者结论:个体化机械通气未降低ARDS患者死亡率,可能与21%患者误分类有关;与肺形态不匹配的通气策略大幅增加死亡率。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与肺形态不匹配的通气策略大幅增加死亡率。
  • 作者认为,改善ARDS表型分型能否降低死亡率应在未来临床试验中评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effect of personalised mechanical ventilation on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remains uncertain and needs to be evaluated. We aimed to test whether a mechanical ventilation strategy that was personalised to individual patients' lung morphology would improve the survival of patients with ARDS when compared with standard of care.

METHODS: We designed a multicentre, single-blind, stratified, parallel-group, randomised controlled trial enrolling patients with moderate-to-severe ARDS in 20 university or non-university intensive care units in France. Patients older than 18 years with early ARDS for less than 12 h were randomly assigned (1:1) to either the control group or the personalised group using a minimisation algorithm and stratified according to the study site, lung morphology, and duration of mechanical ventilation. Only the patients were masked to allocation. In the control group, patients received a tidal volume of 6 mL/kg per predicted bodyweight and positive end-expiratory pressure (PEEP) was selected according to a low PEEP and fraction of inspired oxygen table, and early prone position was encouraged. In the personalised group, the treatment approach was based on lung morphology; patients with focal ARDS received a tidal volume of 8 mL/kg, low PEEP, and prone position. Patients with non-focal ARDS received a tidal volume of 6 mL/kg, along with recruitment manoeuvres and high PEEP. The primary outcome was 90-day mortality as established by intention-to-treat analysis. This study is registered online with ClinicalTrials.gov, NCT02149589.

FINDINGS: From June 12, 2014, to Feb 2, 2017, 420 patients were randomly assigned to treatment. 11 patients were excluded in the personalised group and nine patients were excluded in the control group; 196 patients in the personalised group and 204 in the control group were included in the analysis. In a multivariate analysis, there was no difference in 90-day mortality between the group treated with personalised ventilation and the control group in the intention-to-treat analysis (hazard ratio [HR] 1·01; 95% CI 0·61-1·66; p=0·98). However, misclassification of patients as having focal or non-focal ARDS by the investigators was observed in 85 (21%) of 400 patients. We found a significant interaction between misclassification and randomised group allocation with respect to the primary outcome (p<0·001). In the subgroup analysis, the 90-day mortality of the misclassified patients was higher in the personalised group (26 [65%] of 40 patients) than in the control group (18 [32%] of 57 patients; HR 2·8; 95% CI 1·5-5·1; p=0·012.

INTERPRETATION: Personalisation of mechanical ventilation did not decrease mortality in patients with ARDS, possibly because of the misclassification of 21% of patients. A ventilator strategy misaligned with lung morphology substantially increases mortality. Whether improvement in ARDS phenotyping can decrease mortality should be assessed in a future clinical trial.

FUNDING: French Ministry of Health (Programme Hospitalier de Recherche Clinique InterRégional 2013).

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Constantin JM, Jabaudon M, Lefrant JY, et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med. 2019. PMID: 31399381. doi:10.1016/S2213-2600(19)30138-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。